In 2003, Barbara Hart, JD, served as lead counsel on an antitrust lawsuit focused on tamoxifen (Nolvadex), the most widely prescribed cancer drug in the world.
“We were retained by both individual tamoxifen patients and benefit fund end payers who all felt strongly about this case,” said Ms. Hart, currently chief operating officer at Lowey Dannenberg Cohen & Hart, in White Plains, N.Y.
The lawsuit addressed a controversial deal forged between two drug companies. In March 1993,